• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24394 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early screening in pregnant women with risk factors: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Hybrid-knife endoscopic submucosal dissection]
2024     Scottish Health Technologies Group (SHTG) Digital fracture liaison service
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [General screening: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Artificial urinary sphincter post-prostatectomy]
2024     Agency for Care Effectiveness (ACE) Tolvaptan for treating autosomal dominant polycystic kidney disease
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Iontophoresis for primary palmar and plantar hyperhidrosis]
2024     Agency for Care Effectiveness (ACE) Ruxolitinib for treating graft-versus-host disease
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific analysis of clinical studies in the therapeutic area of wound treatment]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Communication interventions in healthcare that consider race and ethnicity
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure]
2024     Agency for Care Effectiveness (ACE) Nusinersen and risdiplam for treating spinal muscular atrophy
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: unusual vaginal discharge - diagnostic measures and pharmacological treatment]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Use of structured support programmes in the monitoring of heart failure patients - an evidence map]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Locking solutions for central venous catheters: 2024 update
2024     Gesundheit Osterreich GmbH (GOeG) [Long-term effectiveness of early interventions for children and adolescents with psychological stress]
2024     Agency for Care Effectiveness (ACE) Enzyme replacement therapies for Fabry disease
2024     Institute of Health Economics (IHE) Patient initiated follow up in ambulatory secondary care
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding universal screening for congenital cytomegalovirus (CMV) infection to Québec newborn screening program]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: carrier screening - disease selection, considerations, and ethical, psychosocial, sociocultural, organizational, and economic issues]
2024     Agency for Care Effectiveness (ACE) Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine
2024     Institute of Health Economics (IHE) Mammography screening for breast cancer: a replication of a systematic review of observational studies to inform an update of the Canadian Task Force on Preventive Health Care guidelines
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) StellarQ-platform (user interface for professionals)
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: psychosocial interventions in youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2024     Agency for Care Effectiveness (ACE) Burosumab for treating X-linked hypophosphataemia
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) [eConsultation – a digital service centre]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) DentView – a digital self-care guidance tool for oral health
2024     WorkSafeBC Low intensity ultrasound for treating fracture nonunion and short reviews on other bone growth stimulator devices and orthobionomics: second update January 2024
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia
2024     Institute of Health Economics (IHE) Current and future investments for reaching the UNAIDS 95-95-95 HIV targets in Canada: evidence review & cost analysis
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) [Onnikka® lifestyle intervention application for weight management]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) MoodPilot® digital diary
2024     WorkSafeBC Effectiveness of botulinum toxin (botox), A or B, in treating painful neuroma: 2024 update
2024     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy
2024     Institute of Health Economics (IHE) Strategies for optimizing patient flow through the intensive care unit
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Tunstall TSP – a system for receiving and processing personal alarm alerts
2024     WorkSafeBC COVID-19 and perimyocarditis
2024     Agency for Care Effectiveness (ACE) Selexipag for treating pulmonary arterial hypertension
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Liquid biopsy in the diagnosis of ovarian cancer – a compilation of scientific literature]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding a genetic variant of mucolipidosis type II to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024     WorkSafeBC Effectiveness of prolotherapy in rotator cuff tendinopathy
2024     Agency for Care Effectiveness (ACE) Cabotegravir with rilpivirine for treating human immunodeficiency virus type 1 (HIV-1) infection
2024     Institute of Health Economics (IHE) Continuing care design standards to accommodate aging in place in Alberta: rapid review
2024     NIHR Health Technology Assessment programme Infliximab versus alpha interferon in the treatment of Behçet’s disease: the BIO BEHÇET’S RCT
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Indicated prevention of suicide in children and adolescents]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Patiromer (hyperkalaemia in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency echographic multi-spectrometry for bone mineral density assessment]
2024     WorkSafeBC Efficacy/effectiveness of axillary nerve block to treat shoulder pain
2024     Agency for Care Effectiveness (ACE) Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (reassessment after the deadline: pulmonary multidrug-resistant tuberculosis)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of impulse oscillometry (IOS) compared to spirometry]
2024     WorkSafeBC Efficacy/effectiveness of nSTRIDE injection in treating patients with knee osteoarthritis
2024     Agency for Care Effectiveness (ACE) Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quizartinib (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     WorkSafeBC Association between complex regional pain syndrome, ketamine use, lower urinary tract symptoms and erectile dysfunction
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: non-physician prescribers' scope of practice]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2024     WorkSafeBC Noise-cancelling headphones as treatment for PTSD - 2024 update
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: development and evaluation of a software tool based on GPT-4 to help sort documents for literature reviews - a proof of concept]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer) – Addendum to Project A23-104]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding two genetic variants of Zellweger spectrum disorder to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024     WorkSafeBC Causal association between sprain/strain and myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101]
2024     WorkSafeBC Rest as treatment for adhesive capsulitis: 2024 update
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glofitamab (diffuse large B-cell lymphoma, after ≥ 2 prior therapies)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus) – Addendum to Project A23-112]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative Radiation Therapy for Breast Cancer]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Oncological breast cancer care in selected European countries: cross-sectoral cancer care models
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivosidenib (acute myeloid leukaemia with IDH1 R132 mutation, first-line, combination with azacitidine)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Artificial Intelligence in health care with a focus on hospitals: methodological considerations for health technology assessment: a scoping review
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of Deucravacitinib (Sotyktu)
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) - Addendum to Project A23-122]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacokinetics, efficacy and safety of and persistence with treatment with the generic versions of Concerta compared to Concerta]
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Addendum to Project A23-123]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge : optimal modalities for organizing and delivering care and services related to radical cystectomy in Quebec]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system]
2024     Agency for Care Effectiveness (ACE) Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer
2024     NIHR Health Technology Assessment programme Linkage of routinely collected NHS data to evaluate liaison mental health services: challenges and lessons learned
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: the experience of people living with neurocognitive disorders in Quebec]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegzilarginase (hyperargininaemia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet in drug-resistant epilepsy]
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vamorolone (Duchenne muscular dystrophy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Use of telepathology for intraoperative frozen section examination]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Threshold values in health economic evaluations and decision-making